Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model.

DeLeon O, Hodis H, O'Malley Y, Johnson J, Salimi H, Zhai Y, Winter E, Remec C, Eichelberger N, Van Cleave B, Puliadi R, Harrington RD, Stapleton JT, Haim H.

PLoS Biol. 2017 Apr 6;15(4):e2001549. doi: 10.1371/journal.pbio.2001549. eCollection 2017 Apr.

2.

A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support.

Döring M, Borrego P, Büch J, Martins A, Friedrich G, Camacho RJ, Eberle J, Kaiser R, Lengauer T, Taveira N, Pfeifer N.

Retrovirology. 2016 Dec 20;13(1):85. doi: 10.1186/s12977-016-0320-7.

3.

Lineage-Specific Differences between the gp120 Inner Domain Layer 3 of Human Immunodeficiency Virus and That of Simian Immunodeficiency Virus.

Ding S, Medjahed H, Prévost J, Coutu M, Xiang SH, Finzi A.

J Virol. 2016 Oct 28;90(22):10065-10073. Print 2016 Nov 15.

4.

Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus.

Swanstrom AE, Haggarty B, Jordan AP, Romano J, Leslie GJ, Aye PP, Marx PA, Lackner AA, Del Prete GQ, Robinson JE, Betts MR, Montefiori DC, LaBranche CC, Hoxie JA.

J Virol. 2016 Apr 29;90(10):4966-80. doi: 10.1128/JVI.02851-15. Print 2016 May 15.

5.

Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.

Kilgore KM, Murphy MK, Burton SL, Wetzel KS, Smith SA, Xiao P, Reddy S, Francella N, Sodora DL, Silvestri G, Cole KS, Villinger F, Robinson JE, Pulendran B, Hunter E, Collman RG, Amara RR, Derdeyn CA.

J Virol. 2015 Aug;89(16):8130-51. doi: 10.1128/JVI.01221-14. Epub 2015 May 27.

6.

HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage.

Santos-Costa Q, Lopes MM, Calado M, Azevedo-Pereira JM.

Retrovirology. 2014 Nov 25;11:99. doi: 10.1186/s12977-014-0099-3.

7.

HIV-1 endocytosis in astrocytes: a kiss of death or survival of the fittest?

Chauhan A, Tikoo A, Patel J, Abdullah AM.

Neurosci Res. 2014 Nov;88:16-22. doi: 10.1016/j.neures.2014.08.013. Epub 2014 Sep 8. Review.

8.

CKR-L3, a deletion version CCR6-isoform shows coreceptor-activity for limited human and simian immunodeficiency viruses.

Islam S, Kanbe K, Shimizu N, Ohtsuki T, Jinno-Oue A, Tanaka A, Hoshino H.

BMC Infect Dis. 2014 Jul 1;14:354. doi: 10.1186/1471-2334-14-354.

9.

HIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies.

Gorry PR, Francella N, Lewin SR, Collman RG.

J Leukoc Biol. 2014 Jan;95(1):71-81. doi: 10.1189/jlb.0713368. Epub 2013 Oct 24. Review.

10.

Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection.

Cashin K, Jakobsen MR, Sterjovski J, Roche M, Ellett A, Flynn JK, Borm K, Gouillou M, Churchill MJ, Gorry PR.

Retrovirology. 2013 Sep 16;10:98. doi: 10.1186/1742-4690-10-98.

11.

Lineage-specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding.

Finzi A, Pacheco B, Xiang SH, Pancera M, Herschhorn A, Wang L, Zeng X, Desormeaux A, Kwong PD, Sodroski J.

J Virol. 2012 Sep;86(17):8974-86. doi: 10.1128/JVI.01076-12. Epub 2012 Jun 13.

12.

HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

Schader SM, Colby-Germinario SP, Quashie PK, Oliveira M, Ibanescu RI, Moisi D, Mespléde T, Wainberg MA.

Antimicrob Agents Chemother. 2012 Aug;56(8):4257-67. doi: 10.1128/AAC.00639-12. Epub 2012 May 21.

13.

Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.

Espirito-Santo M, Santos-Costa Q, Calado M, Dorr P, Azevedo-Pereira JM.

AIDS Res Hum Retroviruses. 2012 May;28(5):478-85. doi: 10.1089/AID.2011.0124. Epub 2011 Oct 3.

14.

Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.

Haim H, Strack B, Kassa A, Madani N, Wang L, Courter JR, Princiotto A, McGee K, Pacheco B, Seaman MS, Smith AB 3rd, Sodroski J.

PLoS Pathog. 2011 Jun;7(6):e1002101. doi: 10.1371/journal.ppat.1002101. Epub 2011 Jun 23.

15.

Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.

Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L.

J Transl Med. 2011 Jan 27;9 Suppl 1:S1. doi: 10.1186/1479-5876-9-S1-S1. Review.

16.

Current concepts regarding the HTLV-1 receptor complex.

Ghez D, Lepelletier Y, Jones KS, Pique C, Hermine O.

Retrovirology. 2010 Nov 29;7:99. doi: 10.1186/1742-4690-7-99. Review.

17.
18.

Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.

Marcelino JM, Borrego P, Rocha C, Barroso H, Quintas A, Novo C, Taveira N.

J Virol. 2010 Dec;84(23):12429-36. doi: 10.1128/JVI.01102-10. Epub 2010 Sep 15.

19.

Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy.

Ozkaya Sahin G, Bowles EJ, Parker J, Uchtenhagen H, Sheik-Khalil E, Taylor S, Pybus OG, Mäkitalo B, Walther-Jallow L, Spångberg M, Thorstensson R, Achour A, Fenyö EM, Stewart-Jones GB, Spetz AL.

PLoS Pathog. 2010 Sep 2;6(9):e1001084. doi: 10.1371/journal.ppat.1001084.

20.

Restrictions to cross-species transmission of lentiviral infection gleaned from studies of FIV.

VandeWoude S, Troyer J, Poss M.

Vet Immunol Immunopathol. 2010 Mar 15;134(1-2):25-32. doi: 10.1016/j.vetimm.2009.10.005. Epub 2009 Oct 14. Review.

Supplemental Content

Support Center